MSD | AseBio - Asociación Empresas Biotecnología

Contact

Contact information

Merck, Sharp & Dohme de España, SA (MSD)

Sara Cebrián Cuesta, Directora Asociada de Comunicación de MSD

sara_cebrian_cuesta@merck.com

Josefa Valcárcel, 38

Madrid

913210600

913210700

http://www.msd.es

Areas of activities

A. Health Biotechnology
- Areas of activity
  - Biodrugs
  - Vaccines
- Therapeutic areas
  - Analgesia & Pain
  - Dermatology
  - Musculoskeletal system
  - Cardiovascular diseases and circulatory system
  - Infectious diseases
  - Inflammatory diseases
  - Gynaecology and obstetrics
  - Immunology
  - Ophtalmology and optometry
  - Oncology
  - Blood and lymphatic system
  - Digestive system and hepatology
  - Central nervous system
  - Respiratory and pulmonary system
  - Metabolic disorders / Endocrinology

Commissions

Healthcare Committee

Boost the Ecosystem Committee

Description

Today's MSD is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them.

Corporate responsibility

Corporate responsibility is our daily commitment to save and improve lives by discovering better ways to make a difference in everything we do.

http://www.merckresponsibility.com/

Products and services

MSD pipeline has over 20 promising late-stage candidates spanning the stages of life, and we have a presence in more than 100 countries around the world, including emerging markets. MSD also publishes unbiased health information as a non-profit service.

To visit MSD pipeline:
http://www.merck.com/research/pipeline/home.html?WT.svl=content

Areas of interest for future collaborations

Scientific discovery and development have always been the cornerstones of our company. Today, we conduct research in a broad range of therapeutic categories including cardiovascular disease, infectious diseases, vaccines, cancer, neurology and womens health. And, to help achieve our goal of saving and improving lives around the world, we are expanding our capabilities in new areas, such as biologics.

Pipeline

Biotech Sanitaria

Drugs Multinational Subsidiaries
Product / Service	Type	Therapeutic area	Development phase
Pembrolizumab/Olaparib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Olaparib	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Olaparib	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/MK-7684	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/MK-7684	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Lenvatinib/Belzutifan	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab/Lenvatinib	Biodrugs/ Drugs	Oncología	P I
Pembrolizumab/Enfortumab	Biodrugs/ Drugs	Oncología	P III
Pembrolizumab + Lenvatinibb	Biodrugs/ Drugs	Oncología	P II
Pembrolizumab / Olaparib	Biodrugs/ Drugs	Oncología	P III